Results from a Phase II trial for cardiovascular disease with an epigenetic target therapy show promise.
Advertisement
The Scientist
Most Recent
A human trial of a hepatitis C treatment is shut down after one of the participants died.
Mice with inflammatory bowel disease harbor gut bacteria that damage host DNA, predisposing mice to cancer.
A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.
A researcher from the John Wayne Cancer Institute has settled his scientific misconduct case with the Office of Research Integrity.
A slight flaw in a study on the effectiveness of a drug widely used to combat shock in critically injured patients almost gets a Danish researcher sued for millions.
Lymphatic vessels grow towards two chemokines, revealing signals that could be important in cancer metastasis.
To cope with a growing shortage of hearts, livers, and lungs suitable for transplant, some scientists are genetically engineering pigs, while others are growing organs in the lab.
Like commensal gut organisms, skin microbiota appear to help the mammalian immune system mature and stay regulated.
After years of complaints, the European Commission proposes ways to fix its system in an effort to reinvigorate research on the continent.
Follow The Scientist
Advertisement
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
